The perceived increased personal risk associated with these recent can you trade coin on coinbase how to open a coinbase wallet may deter qualified individuals from accepting these roles. In addition, submission of an application for marketing approval to the relevant regulatory agency following completion of clinical trials may not result in the regulatory agency approving the application if applicable regulatory criteria are not satisfied, and may result in the regulatory agency requiring additional testing or information. At present, we offer only reprints and e-copies of published materials that cater primarily to the life science industries. The Company generally will be entitled to a deduction on the date of etoro 10 usa fxcm contact number uk in an amount equal to the ordinary income recognized by the recipient. Prior to the Merger, we did not compensate our directors for director services to the Company. As a result, it may be more difficult for us to achieve regulatory approval or market acceptance of our products. These lawsuits generally relate to the validity and infringement of patents or proprietary rights of third parties. The holders of the outstanding shares of common stock of Bio-Path immediately before the Merger received 2. Bio-Path intends to maximize the quality and frequency of these transactions, while minimizing the time and cost to achieve meaningful candidates for out-licensing. An approvable letter will usually contain a number of conditions that must be met in order to secure final approval of the new drug application and authorization of commercial marketing of the drug for certain indications. The Company extends unsecured credit to its customers in the normal course of business. Effective Date. To this end, Bio-Path intends to have an intellectual property program directed at developing proprietary rights in technology that Bio-Path believes will be important best performing philippine stocks how much is etrade per month its success. This is a drawback which the project will have to address. Bio-Path currently does not have any significant facilities. Under those rules, beneficial ownership includes any shares as to which the individual has sole or shared voting power or low cost stock trading websites robinhood checking sign up power and also any shares which the individual has the right to acquire within 60 days of the date hereof, through the exercise or conversion of any stock option, convertible security, warrant or other right. Mark Scharmann 6. The Company currently anticipates that access tradestation strategy builder what is etf daily news would complete such funding approximately six months after preferred stock warrants enata pharma statistics on penny stocks closing of the Merger. The Company has targeted several potential acquisition opportunities.
These provisions could also limit the price that investors might be willing to pay in the future for shares of our Common Stock. It eliminates the high risk currently associated with corporate re-use of copyrighted articles. Moreover, positive results of non-clinical tests will not necessarily indicate positive results in subsequent clinical trials in humans. Halm, Anthony. Upon approval of the BP Any failure of our internal controls or our ability to provide accurate financial statements could cause the trading price of our common stock to decrease substantially. The natural person with voting and investment control over the shares held by the seller security holder is G Tyler Runnels. Mark Scharmann 6. Phase I clinical trial estimate includes cost of BP These provisions in our articles of incorporation will generally not limit liability under state or federal securities bank nifty option intraday tips duplitrade copy trading platform. Payment for future patent expenses as they are incurred. We may not be able to successfully integrate acquired businesses or realize projected cost savings and synergies in connection with those acquisitions on the timetable contemplated or at hamilton online ai trading spread trading futures pdf. The SEC has adopted rules implementing Section for public companies as well as disclosure requirements. Upon disposition of the shares purchased pursuant to the stock option, the recipient will recognize long-term or short-term capital gain or loss, as the case may be, equal to the difference between the amount realized on such disposition and the basis for such shares, which basis includes the amount previously recognized by the recipient labu swing trading forex trading online simulator game ordinary income. Important factors that may cause actual results to differ from projections include:. State or other jurisdiction of incorporation. Incentive stock option grants shall be made in accordance with Section of the Internal Revenue Code. Scientific Advisory Board.
Reimbursements to M. The Committee will have the authority to determine, within the limits of the express provisions of the Stock Incentive Plan, the individuals to whom awards will be granted, the nature, amount and terms of such awards and the objectives and conditions for earning such awards. Expiration Date. The following descriptions of our capital stock are only summaries and do not purport to be complete. Percentage based upon 12,, shares of common stock outstanding as of December 21, Recent Sales of Unregistered Securities. Our service alleviates the need for the content users to contact any publishers or obtain permissions themselves. He has extensive experience in high-acuity, high-volume emergency departments with large trauma referral bases. Management has budgeted several payments to be made to M. Bio-Path was founded to focus on bringing the capital and expertise needed to translate drug candidates developed at MD Anderson and potentially other research institutions into real treatment therapies for cancer patients. Development Expense. February 6, As with the FDA, we cannot predict if or when we may obtain these regulatory approvals. The rights of the holders of common stock will be subject to and may be adversely affected by the rights of the holders of any preferred stock that may be issued in the future. The Company reviews long-lived assets for impairment when circumstances indicate the carrying amount of an asset may not be recoverable. There has only been limited trading in our common stock. The investors took their shares for investment purposes without a view to distribution and had access to information concerning Derycz and our business prospects, as required by the Securities Act. Minority Interest in income. The risks that we face in connection with these collaborations include, but are not limited to, the following:. Accordingly, the Board does not anticipate declaring any dividends in the foreseeable future.
If we fail to attract, train and retain sufficient numbers of these highly qualified people, our prospects, business, financial condition and results of operations will be materially and adversely affected. We believe that our audits provide a reasonable basis for our opinion. Phase III. Bud Headman, Managing Mem. The transaction engine will allow the Company to effectively automate and manage order flow for the various e-commerce, licensing and production needs of the Company , as well as manage royalty payments to rights holders. Until we assume operating control of the businesses we purchase, we may not be able to ascertain the actual value or understand the potential liabilities of the acquired entities. Litigation or interference proceedings could force us to:. Any failure by us or our collaborators to obtain, or any delay in obtaining, regulatory approval could adversely affect the marketing of any drug product candidates developed by us, our ability to receive product revenues, and our liquidity and capital resources. Any inability to protect intellectual property rights in the United States and foreign countries could limit our ability to manufacture or sell products. A voluntary coalition of medical journal editors has adopted a resolution to publish results only from those trials that have been registered with a no-cost, publicly accessible database, such as www. In both the. Incentive Stock Options. Item 2. For the foreseeable future, we intend to fund our operations and capital expenditures from limited cash flow from operations and our cash on hand. The Company extends unsecured credit to its customers in the normal course of business. We intend to establish relationships with multiple regulatory consultants for our existing clinical trials, although there is no guarantee that the consultants will be available for future clinical trials on terms acceptable to us.
Bio-Path will face significant competition in seeking necessary and appropriate collaborators. The total amount of shares subject to the Plan is 1, shares. Litigation or interference proceedings could force us to:. Under this rule, strap option strategy day trading laptop computers who sell penny stocks must provide purchasers of these stocks with a standardized risk-disclosure document prepared by the SEC. The Company currently anticipates that it would complete such funding approximately six months after the closing of the Merger. The shares of preferred stock or any series thereof may have full or limited voting powers or be without voting powers. While we do not expect our sales to increase seven times during fiscalwe do anticipate that our sales will increase significantly. Scientific Advisory Board. We can give you no assurance that we can find satisfactory replacements for these key executive officers at all, or on terms that are not unduly expensive or burdensome to our company. Results of Operations. Rsi period for day trading best no deposit bonus 2020 forex Merger. Expenditures, including equipment used in research and development, are expensed as incurred. In addition, the emphasis on managed care in the United States has increased, and will continue to increase the pressure on the pricing of pharmaceutical products and medical devices. Net cash used in operating activities. State or other jurisdiction of incorporation. The biographies of those individuals currently serving as directors and executive officers of the Company are set forth below:. Morris 2 4. The shares of common stock are fully paid and nonassessable. Public company expense We are a development stage company developing a variety of capabilities on an organic basis as well as through acquisition.
The Company is not currently subject to the proxy rules under the Securities Exchange Act of , as amended and therefore, no information statement was filed with the Securities and Exchange Commission. The Company has made a preliminary allocation of purchase price to the fair value of the acquired assets as follows:. Beneficial ownership is determined in accordance with the rules of the SEC and includes general voting power or investment power with respect to securities. Such concentrated control of the Company may adversely affect the price of our Common Stock. In addition, if we fail to comply with new or changed laws, regulations and standards, regulatory authorities may initiate legal proceedings against us and our business and our reputation may be harmed. The price of the common stock offered for sale by the selling security holders was arbitrarily determined. If we acquire additional businesses, those businesses may require substantial capital. In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Derycz Scientific, Inc. Relationship with MD Anderson. Detection of activity of BP At any time during the day period or at any time thereafter, the FDA may halt proposed or ongoing clinical trials until the FDA authorizes trials under specified terms.
We may be required to defend lawsuits or pay damages for product liability claims. A day waiting period after the citibank forex trading account define pattern day trading of each investigationalnew drug application is required prior to commencement of clinical testing in humans. Description of Business. Our goal is to become the leading provider of repurposed content in the United States and Europe. Morris 2 4 1, 4. The value of the purchase price allocated to the fixed assets was based upon an appraisal performed by Winternitz Appraisal Service, Inc. Our ability to implement a successful business plan remains unproven and no assurance can be given that we will ever generate sufficient revenues to technical analysis excel template with trading strategy backtesting evening star candle pattern bulk our business or make a profit. In addition, they could dictate the management of our business and affairs. The specific activities and budget estimates discussed above are based on current information available. In addition, submission of an application for marketing approval to the relevant regulatory agency following completion of clinical trials may not result in the regulatory agency approving the application if applicable regulatory criteria are not satisfied, and may result in the regulatory agency requiring additional testing or information.
Concerns about the safety and efficacy of our products could limit its future success. If there is no effective registration statement registering the underlying shares for a consecutive day period, these warrants contain cashless exercise provisions that dividend stock payout dates best 25 dividend stocks in various stocks the holder to exercise the algorand ico how to buy omisego with bitcoin for a lesser number of shares of common stock in lieu of paying cash. There were no unexercised options, stock that has not vested, or equity incentive plan awards for any preferred stock warrants enata pharma statistics on penny stocks our named executive officers outstanding as of June 30, Additionally, favorable business terms agency discounts similar to the advertising industry will be aggressively pursued. Information on our website is not part of this Registration Statement. Publisher In-House Capabilities — Some large publishers have developed in-house capabilities to service the content re-use market. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. Sales and Cost of Goods Sold. The Company has no impairment issues to disclose. Date of report date of earliest event reported : February 19th, This drug has been granted orphan drug status by the FDA. The disclosures set forth in Item 2. Summary 1. Although the Company believes that its plans, intentions and expectations reflected in or suggested by the forward-looking statements in this prospectus are reasonable, the Company cannot assure potential investors that these plans, intentions or expectations will be achieved. Derycz's salary is allocated to his duties as a director of the Company. Historically, the requirements governing the conduct of clinical trials and product approvals, and the time required for approval, have varied widely from country to country. Following completion of the exchange transaction, Reprints became a wholly-owned subsidiary of the Company. There were no grants of google authenticator key for coinbase reddit coinbase how long to get coin options made to any officer or director of Ogden Golf during the fiscal year ended June 30, A sale for less than the option price results in a capital loss. Circumstances that could trigger an impairment test include; a significant adverse change in the business climate or legal factors; an adverse action or assessment by a regulator; unanticipated competition; the loss of key personnel; the likelihood that a reporting unit or significant portion of a reporting unit will be sold or otherwise disposed of; the results of testing for recoverability of a significant asset group within a reporting unit, and the recognition of a goodwill impairment loss in the financial statements of a subsidiary that is a component of a reporting unit.
We intend to implement acquisitions primarily through stock transactions, supplemented only when necessary with a cash component. Summary Consolidated Financial Data. This was the result of revenues increasing at a faster pace than our operating costs. Upon the lapse of the restrictions and the issuance of the earned shares, the participant will recognize ordinary taxable income in an amount equal to the fair market value of the common stock received and the Company will be entitled to a deduction in the same amount. We do not anticipate that we will have any revenues for the foreseeable future and accordingly, we do not anticipate that we will pay any dividends for the foreseeable future. It is recommended that the UN international codes should be adopted, and that data from the national statistics offices be mapped to these codes. We will pay the costs and fees of registering the common stock, but each selling security holder will pay his or her own brokerage commissions, discounts or other expenses relating to the sale of the common shares. Kim, Managing Member. Our business will expose us to potential product liability risks inherent in the clinical testing and manufacturing and marketing of pharmaceutical products, and we may not be able to avoid significant product liability exposure. Our securities are not currently listed on any securities exchange, nor are they quoted on the Over-the-Counter Electronic Bulletin Board. Although we believe that our current cash resources will be sufficient to sustain our current operations for several years, we may need to obtain additional cash resources during the next year if we are able to acquire complementary businesses. We are presently evaluating and monitoring developments with respect to new and proposed rules and cannot predict or estimate the amount of the additional compliance costs we may incur or the timing of such costs.
As with the FDA, we cannot predict if or when we may obtain these regulatory approvals. Item 2. The warrants may also be exercised on openledger dex exchange buy bitcoin cheap uk cashless basis from which we would receive no proceeds if, at the time of exercise, the warrant shares have not been subject to an effective registration statement for a consecutive day period. Shares Rounded. Please review our articles of incorporation and bylawscopies of which have been filed herewith, as well as the applicable statutes of the State of Nevada for a more complete description of the rights and liabilities of holders of our shares. The Company may be exposed to risk for the amounts of funds held in one bank in excess of the insurance limit. The Company sells prints to an international base of customers. Our business strategy includes pursuing acquisitions. The Company has a salary reduction plan established under Internal Revenue Code Section k covering substantially all employees. The Company is not bitcoin malaysia exchange buy ethereum with coinbase subject to the proxy rules under the Securities Exchange Act ofas amended and therefore, no information statement was filed interactive brokers trader workstation tws expat international stock brokerage panama panama the Securities and Exchange Commission. Organic Growth.
Third Quarter. Proceeds from advance from stockholder. We expect to be subject to infringement claims from time to time in the ordinary course of business, and third parties could assert infringement claims against us in the future with respect to products that we may develop or license. Reimbursement of past patent expenses 9. The plan of operation for the initial twelve month period after the closing of the Merger focuses on taking actions to initiate programs that are necessary to achieve the following three key milestones:. MD Anderson will treat more than 80, patients this year, of which approximately 11, will participate in therapeutic clinical research exploring novel treatments—the largest such program in the nation. The rights of the holders of common stock will be subject to and may be adversely affected by the rights of the holders of any preferred stock that may be issued in the future. Any future determination to pay dividends on our common stock will depend upon our results of operations, financial condition and capital requirements, applicable restrictions under any credit facilities or other contractual arrangements and such other factors deemed relevant by our Board of Directors. Broker-dealers may receive commissions or discounts from the selling security holders or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser in amounts to be negotiated. The Company has the ability to generate and distribute custom publications. Interest of Named Experts and Counsel. As of February 14th, there were 41,, shares of common stock outstanding and approximately stockholders of record. At the closing of the transaction contemplated by the Share Exchange Agreement, the Company acquired all of the outstanding shares of Reprints from the shareholders of Reprints and issued 8,, of its common shares to the shareholders. Officers and stockholders of Ogden Golf have made loans to Ogden Golf. Estimated solely for the purpose of calculating the registration fee pursuant to Rule o under the Securities Act of Statements contained in this prospectus concerning the contents of any contract or any other document are not necessarily complete. To date, we have financed our operations through equity financing. There were no changes in or disagreements with our accountants on accounting and financial disclosure during the last two fiscal years or the interim period from July 1, through the date of this prospectus. Under such provisions, the director, officer, corporate employee or agent who in his capacity as such is made or threatened to be made, party to any suit or proceeding, shall be indemnified if it is determined that such director or officer acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of our company. Doug Steiner, Managing Member.
A sale for less than the option price results in a capital loss. Tom Garrison 2 5 1,, 3. In addition, under certain circumstances, the issuance of preferred stock could adversely affect the voting power of the holders of the common stock. This amount excludes payment of any fund raising commissions and legal expenses. Such responsibilities include complying with Federal securities laws and making required disclosures on a timely basis. As of December 21, , we had 12,, shares of common stock outstanding and the book value of each share was nominal. Recently, we have taken measures to address and improve our financial reporting and compliance capabilities and we are in the process of instituting changes to satisfy our obligations in connection with becoming a public company, when and as such requirements become applicable to us. Digital Print-on-Demand Services for copyright and regulatory sensitive documents. The failure of any of our collaborative relationships could delay drug development or impair commercialization of our products. The price of the common stock offered for sale by the selling security holders was arbitrarily determined. We have not paid any dividends nor do we anticipate paying any dividends on our common stock in the foreseeable future. Our future success will depend to a substantial extent on our ability to identify new market trends on a timely basis and develop, introduce and support proposed products on a successful and timely basis. If any of the following risks actually occurs, our business, financial condition or results of operations could be harmed. The allocation to the customer lists was made based upon a preliminary evaluation made by management. Capital lease obligation. Historically, the requirements governing the conduct of clinical trials and product approvals, and the time required for approval, have varied widely from country to country. These lawsuits generally relate to the validity and infringement of patents or proprietary rights of third parties. The FDA may require additional animal testing after an initial investigational new drug application is approved and prior to Phase III trials. In , a public registry of open clinical trials involving drugs intended to treat serious or life-threatening diseases or conditions was established under the Food and Drug Administration Modernization Act, or the FDMA, in order to promote public awareness of and access to these clinical trials.
Sutila, Monique. The Board of Directors may at any time amend or terminate the Stock Incentive Plan, provided that no such action may be taken that adversely affects any rights or obligations with respect to any awards theretofore made under the Stock Incentive Plan without the consent of the recipient. Assumes that all shares offered hereby will be resold by the selling security holders after this offering. In addition, the results of early human clinical trials may not be predictive of results that will be obtained in larger scale, advanced stage clinical trials. Published content is also used effectively for internal corporate training and education, as well as for research and regulatory needs The publishing industry is eager to expand their ancillary revenue streams nadex stop loss plugin nadex account value chart this type of revenue typically fall directly to their bottom-line. Morris after the Merger include ishares owned by Hyacinth Resources, ii and 1, Shares attributed to his Douglas P. SARs must be exercised within a period fixed by the Compensation Committee that may not exceed ten years from the date of grant. Certain Relationships and Related Transactions. Street, NE, Washington, D. Management has budgeted several payments to be made to M. Distribution to Stockholder. Since our inception, we have funded our operations primarily through private sales of equity securities. Executive Compensation. However, if the financial condition of any customers or debtors was to deteriorate and their ability to make required payments became impaired, an increase in the allowance may be required. Automated trading firm quantum computing companies monitors for day trading, address and telephone number of Agent for Service. Outsourcing and referral business will be sought through the publisher partner network. The shares listed as being owned by Mr. Ahlberg's employment contract as Head of Corporate Services of Reprints Desk and as a director of the Company has a three year term beginning July 1, Section requires management of public companies to evaluate the effectiveness of intraday entry strategies how many day trades can you make in one day control over financial reporting and the independent auditors to attest to the effectiveness cancer treatment stocks penny stocks how to cancel robinhood gold such internal controls and the evaluation performed by management. The investors took their shares for investment purposes without a view to distribution and had access to information concerning Derycz and our business prospects, as required by the Securities Act.
We issued the remaining shares of outstanding common stock in private transactions in reliance upon exemptions from registration under the Securities Act. We currently have 53 record holders of our common stock. Total Current Liabilities. On November 16, , we issued 8,, shares of common stock to the six stockholders of Reprints Desk pursuant to a share exchange agreement whereby Reprints Desk became our wholly owned subsidiary. The natural person with voting and investment control over the shares held by the selling security holder is Susan E. Derycz Scientific purchased a majority interest in Pools Press, Inc. Effective Date. During this period, third parties would not be permitted to obtain FDA approval for a similar or identical drug through an Abbreviated NDA, which is the application form typically used by manufacturers seeking approval of a generic drug. Derycz is not presently a party to any pending or threatened legal proceedings. Product liability is a major risk in testing and marketing biotechnology and pharmaceutical products. The Company is not currently subject to the proxy rules under the Securities Exchange Act of , as amended and therefore, no information statement was filed with the Securities and Exchange Commission.
If our financial and managerial controls, reporting systems or procedures fail, we may not be able to provide accurate financial statements on a timely basis or comply with the Sarbanes-Oxley Act of as it applies to us. Bailey, Dr. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised by its counsel preferred stock warrants enata pharma statistics on penny stocks, in the opinion of the SEC, tastyworks and td ameritrade can you make more money trading options or stocks indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. Ogden Golf Co. The Company extends credit based on an evaluation of the customer's financial condition, generally without collateral. The Company does not anticipate incurring any losses related to these credit risks. Our ability to develop and commercialize drugs depends in significant part on our ability to:. The performance targets will also be determined by the Committee. Common Stock. Although no agreement exists between the Company and Ms. A voluntary coalition of medical journal editors has adopted a resolution to publish results only from those trials that have been registered with a no-cost, publicly accessible database, algo trading course leonardo trading bot download as www. We may be forced to accept funds on terms or pricing that is highly dilutive or otherwise onerous to other equity holders. All of the amounts shown are estimates except the Securities and Exchange Commission Registration Fee:. Total Stockholder's Equity. We can give you no assurance that day trading morons cronos cannabis corp stock can find satisfactory replacements for these key executive officers at all, or on terms that are not unduly expensive or burdensome to our company.
B ecause the publishers set the price for each order and do not generally grant significant discounts we expect that our cost of goods sold will keep pace with our revenue growth, unless additional publisher discounts can be achieved. We relied upon the exemption from registration as set forth in Section djia futures trading reddit forex robot good 2 of the Securities Act for the issuance of these shares. Our preferred stock may be designated into series pursuant to authority granted by our articles of incorporation, and on approval from ourboard of directors. As of September 30, and June 30,the Company had no employee options forex ea that really works intraday point and figure charting software or outstanding. As disclosed under Item 2. SARs may be granted at the time futures trading software electronic trading binary options auto trading script the stock option grant or, with respect to non-qualified stock options, at any time prior to the exercise of the stock option. Periods ended June 30. The failure of any of our collaborative relationships could delay drug development or impair commercialization of our products. Capital lease obligation, current. Any product for which we or our pharmaceutical company out-license partner obtain marketing approval, along with the facilities at which the product is manufactured, any post-approval clinical data and any advertising and promotional activities for the product will be subject to continual review and periodic inspections by the Best times days to trade stocks etoro copy review and other regulatory agencies. Period. In addition to monthly rentals, the lease requires the payment of real estate taxes and maintenance. Certain provisions of the Stock Incentive Plan relating to performance-based awards under Section m of the Internal Revenue Code will expire on the fifth anniversary of the effective date.
Upon approval of the BP We anticipate that the competition with our products and technologies will be based on a number of factors including product efficacy, safety, availability and price. Property and equipment are stated at cost and are depreciated using the straight-line method over their estimated useful lives of years. The natural person with voting and investment control over the shares held by the selling security holder is D. Published content is typically re-used by corporate organizations for the following purposes:. Reprints began generating revenue in April Standard aggressive advertising is increasingly viewed as insulting and intrusive. We have filed with the SEC a registration statement on Form SB-2 under the Securities Act with respect to the common stock being offered in this offering. Hyacinth Resources 7. Historically, the requirements governing the conduct of clinical trials and product approvals, and the time required for approval, have varied widely from country to country. Periods ended June 30,. The following table sets forth the names of the selling security holders who may sell their shares under this prospectus from time to time. Instead, it will leverage an executive team with expertise in the selection and management of high quality contract manufacturing and regulatory firms. If we fail to attract, train and retain sufficient numbers of these highly qualified people, our prospects, business, financial condition and results of operations will be materially and adversely affected. Single copies of published articles are also used by these same companies and other companies for research and regulatory purposes.
Although no agreement exists between the Company and Ms. Content users will only need to go to one website or contact one sales representative to obtain published materials, regardless of the publisher. Peter Derycz founded Reprints as its President in Pools Press contributed the remainder of the revenue. However, the amount of funds actually spent on specific projects or the priorities of which projects are actually undertaken may change as new information becomes available in the future. Bio-Path will face competition based on the safety and efficacy of virtual commodity trading app forex trading tips risk tolerance drug candidates, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent position and other factors. We compete with companies in the following segments. Medicare, Medicaid what is really going on with the stock market amazon stock dividend yield other governmental healthcare programs govern drug coverage and reimbursement levels in the United States. The most likely outcome of an out-license of a Bio-Path drug to a pharmaceutical partner will be that the pharmaceutical partner will be responsible for manufacturing drug product requirements. Bio-Path intraday gold level how to make money futures trading no experience in designing, conducting and managing the clinical testing necessary to obtain such regulatory approval. It is our present policy to retain earnings, if any, for use in the development of our business. The factors considered were:. Assumes that all shares offered hereby will be resold by the selling security holders after this offering. As a result of the Merger Transaction, the former shareholders of Bio-Path, now, as a group, have voting control of the Company. Penny Family LP. Peter Derycz employment agreement. Niche Publishing. Patent litigation and other proceedings may also absorb significant management time. A drug candidate may fail at any point during this process.
Morris, Dr. All World Consortium. The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States, and many companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries. If any of the following risks actually occurs, our business, financial condition or results of operations could be harmed. Since we recently commenced operations, we may not have anticipated all developments and problems that may occur and the amount of time and capital required to become profitable and cash flow positive. In addition to monthly rentals, the lease requires the payment of real estate taxes and maintenance. Percentage based upon 12,, shares of common stock outstanding as of December 21, State tax, net of federal benefit. The statements contained in or incorporated into this offering that are not historic facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward-looking statements. Securities Issuance. Other current liabilities. Out-Licenses and Other Sources of Revenue. The loan was repaid upon the sale of our building. We are subject to Sarbanes-Oxley and the reporting requirements of federal securities laws, which can be expensive. The Company will be entitled to a corresponding deduction. These expenses will continue to rise during fiscal as we continue to add employees to develop our computer system and to handle the rapidly increasing sales volume.
Performing the remaining pre-clinical development work for BP We are a development stage company developing a variety of capabilities on an organic basis as well as through acquisition. Annual maintenance fees 7. Third Quarter. Derycz-Kessler, she may receive compensation in connection with that offering through T. The selling security holders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus as supplemented or amended to reflect such transaction. Brick and Mortar, LLC. For example, there are certain cancers that are primarily treated only in a comprehensive cancer center; of which there are approximately forty in the US and perhaps two hundred throughout the world. Retained Rights. Phase III. Bio-Path intends to hire additional employees during the next several months.
Derycz Scientific, Inc. Federal legislation was introduced in the fall of to expand www. The natural person with voting and investment control over the shares held by the selling security holder is Seth Farbman. It is generally based on academic and other publications that are not produced for purposes of securities offerings or economic analysis. At this time there is no public trading interactive brokers excel software training nano second stock trade for our common stock. Amendment and Termination. Unexpected costs and operating deficits, and lower than expected sales and revenues. Executive Compensation. Reprints, our main operating subsidiary, was incorporated in January and only started procuring reprinted articles in April
All of the amounts shown are estimates except the Securities and Exchange Commission Registration Fee:. Additionally, published articles are increasingly seen as useful marketing and information dissemination tools as they provide a third party, unbiased endorsement of a company, product or service. Our patents and licensed patent rights may be challenged, invalidated, infringed or circumvented, and the rights granted in those patents may not provide proprietary protection or competitive advantages to us. We have established all of the necessary components to facilitate sales and purchases of published materials to satisfy the demand for the above listed end-products as well as many others. All outstanding shares of common stock are, and the shares of common stock offered hereby will be, when issued, fully paid and nonassessable. If our capital resources are insufficient, particularly if we pursue acquisition opportunities, we will have to raise additional funds through equity or debt financing. Bio-Path believes that if Bio-Path obtains adequate financing, Bio-Path will be positioned to translate current and future MD Anderson technology into real treatments for cancer patients. Those standards require that we plan and perform the audits to obtain reasonable assurance whether the financial statements are free of material misstatement. Rapid technology change and obsolescence. It is recommended that the UN international codes should be adopted, and that data from the national statistics offices be mapped to these codes.